Blood-Borne Diseases

In the third installment of our series on preparedness, Gavin Harris, MD, discusses the principles and challenges of biorisk management, focusing on infectious disease threats and containment strategies.

Promptly vaccinating the "ring" of contacts and contacts-of-contacts along with standard infection control measures interrupted Ebola transmission in the DRC.

Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.

The federal government is working to provide greater access to testing and treatment.

Accessibility to direct-acting antivirals affecting low and middle-income countries.

Study reveals HEV adaptation during treatment.

Sustained virologic response (SVR) and sociodemographic factors were found to be associated with long-term improvements in health-related quality of life in patients with hepatitis C (HCV).

People who inject drugs (PWID) are at a higher risk for hepatitis C and HIV. A new study examined point of care initiatives and how to better support this population with intervention efforts.

Changes encompass clarification of recommendations for scheduled vaccinations and the addition of the RSV vaccines for the first time.

A new study warns an increase in costs could lead to new infections.

Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.

Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.

A clinician utilizes mobile clinics to bring a hybrid of primary and urgent care to marginalized populations and help people overcome barriers and gets them into the continuum of care.

Infants with HIV could be spared from requiring lifetime ART if treated within hours of birth to disrupt formation of HIV viral reservoirs.

The expanded indication to those with severe hepatic impairment has already been granted in the US and EU.

Several trial participants experienced concerning hepatobiliary events.

The vaccine is steps behind another Chikungunya vaccine candidate from Valneva, which is currently under priority review by the FDA.

The CDC made this recommendation after reviewing relevant literature, and noting that complete testing jumped from about only two-thirds of patients to nearly all patients.

The vaccine has been approved since late 2019 for adults age 18 and older.

The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.

So far, the Virginia Mason Medical Center in Seattle has confirmed 33 patients have been infected with Klebsiella pneumoniae bacteria, 9 of whom have died.

Some chronic hepatitis B patients experienced a dramatic decrease in hepatitis B surface antigen (HBsAg) after receiving a COVID-19 vaccine. Could there be a correlation?

February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.

This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.